Mainstream

Bio-Techne outlines 100 basis points margin expansion for FY26 following Exosome Diagnostics divestiture

Bio-Techne outlines 100 basis points margin expansion for FY26 following Exosome Diagnostics divestiture

Post ContenttechRead More

You might also be interested in reading Blackrock Outlines Why SEC ‘Must’ Approve Spot Ethereum ETFs.

August 6, 2025
In Mainstream